[Bioartificial liver support for acute liver failure. First case treated in Spain]

Research aimed at developing artificial liver support systems has experienced a notable increase in the last decade. Hybrid systems including bioreactors containing hepatocytes which are perfused by liver failure patients blood or plasma have been deviced for the first time. The purpose of such a strategy is to substitute, at least in part, the impaired hepatic function thus improving the prognosis of patients with severe acute or chronic liver diseases.

In the present paper, we report the first such a case treated in Spain in the context of a controlled, randomized, multicenter international study aimed at investigating the usefulness and safety of a bioartificial liver support system based on cryopreserved porcine hepatocytes in patients with acute liver failure or having a non-functioning primary graft after liver transplantation.

In this first experience, two sessions of treatment could be completed before a patient with acute liver failure underwent a successful emergency liver transplantation. After more than two years of follow-up, the patient is in her normal life activities and she has not presented any adverse event related to the bioartificial liver support therapy so far.

Bioartificial liver support systems are starting to be available for use in clinical practice. Yet it is mandatory to establish their safety and efficacy before a widespread recommendation.